Harmony Biosciences Holdings (HRMY) Total Debt (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Total Debt data on file, last reported at $158.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 9.6% year-over-year to $158.8 million; the trailing twelve-month figure through Mar 2026 stood at $158.8 million (down 9.6% YoY), and the FY2025 full-year result was $163.7 million, down 8.7% from the prior year.
• Total Debt eased to $158.8 million in Q1 2026, from $163.7 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $197.1 million in Q3 2023 to a low of $158.8 million in Q1 2026.
• A 5-year average of $183.4 million and a median of $190.0 million in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt grew 2.82% in 2023 and slipped 9.6% in 2026, its largest moves.
• Tracing HRMY's Total Debt over 5 years: stood at $191.6 million in 2022, then climbed by 1.0% to $193.6 million in 2023, then retreated by 7.39% to $179.3 million in 2024, then fell by 8.7% to $163.7 million in 2025, then retreated by 2.96% to $158.8 million in 2026.
• Business Quant data shows HRMY's Total Debt at $158.8 million in Q1 2026, $163.7 million in Q4 2025, and $168.5 million in Q3 2025.